[EN] NITROGEN- HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS [FR] COMPOSÉS AZOTÉS HÉTÉROCYCLIQUES CONVENANT COMME INHIBITEURS DE LA PHOSPHODIESTÉRASE 10
[EN] NITROGEN- HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS [FR] COMPOSÉS AZOTÉS HÉTÉROCYCLIQUES CONVENANT COMME INHIBITEURS DE LA PHOSPHODIESTÉRASE 10
[EN] FUSED PYRIMIDINES AS AKT INHIBITORS<br/>[FR] PYRIMIDINES CONDENSÉES EN TANT QU'INHIBITEURS D'AKT
申请人:BAYER SCHERING PHARMA AG
公开号:WO2010091824A1
公开(公告)日:2010-08-19
The present invention relates to compounds of formula (I), a N-oxide or tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the imidazole to which it is fused, R4, R6, R7, R10, m and n have the meanings as given in the description and the claims, which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals.
Synthesis and antimicrobial evaluation of substituted benzimidazolyl fluoroquinolones under conventional and microwave irradiation conditions
作者:Batthini Guruswamy、Ramakrishnan Arul
DOI:10.1515/hc-2012-0082
日期:2012.10.1
were prepared using a conventional methodology and with the help of a microwave irradiation technique. The structures of the synthesized compounds were established on the basis of spectral and analytical data. The antimicrobial activities of newly synthesized compounds were evaluated against a number of microorganisms by using ciprofloxacin as reference. Many of the evaluated compounds exhibit remarkable
The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products.
The present inventors have found that derivatives having a substituent introduced into the γ-position of proline represented by the formula (I)
wherein each symbol is as defined in the specification, have a potent DPP-IV inhibitory activity, and completed the present invention by increasing the stability.
The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products.
The present inventors have found that derivatives having a substituent introduced into the &ggr;-position of proline represented by the formula (I)
1
wherein each symbol is as defined in the specification, have a potent DPP-IV inhibitory activity, and completed the present invention by increasing the stability.
ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS
申请人:Allen Jennifer R.
公开号:US20110306590A1
公开(公告)日:2011-12-15
Aryl- and heteroaryl-nitrogen heterocyclic compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like.